title: Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia.
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Houry
authors.initials: H
authors.lastname: Leblebjian
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Noonan
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Claudia
authors.initials: C
authors.lastname: Paba-Prada
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Steven P
authors.initials: SP
authors.lastname: Treon
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Jorge J
authors.initials: JJ
authors.lastname: Castillo
authors.affiliation: Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts.
authors.forename: Irene M
authors.initials: IM
authors.lastname: Ghobrial
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D011719:Pyrazines / Q000008:administration & dosage; D012189:Retrospective Studies; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy* / Q000401:mortality*
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D003520:Cyclophosphamide